Sionna Therapeutics

News

Share in cystic fibrosis firm Sionna rise sharply after IPO

Sionna has closed its IPO, raising $191m for cystic fibrosis candidates that it thinks could be more effective than rivals from Vertex.

News

Two more biotechs join IPO waiting list

Odyssey and Sionna have filed to carry out IPOs on the Nasdaq, following after Metsera and Maze which filed earlier in January.

News

Boundless Bio files IPO, and other biotech financings

Boundless Bio made a play to become the seventh US biotech to seek a public listing in 2024, ending a brief hiatus in IPO activity after a busy start to the year.

Share in cystic fibrosis firm Sionna rise sharply after IPO

Two more biotechs join IPO waiting list

Boundless Bio files IPO, and other biotech financings

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks